Bokf Na Trims Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bokf Na lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,069 shares of the medical equipment provider’s stock after selling 165 shares during the period. Bokf Na’s holdings in Zimmer Biomet were worth $216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in ZBH. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet during the 4th quarter worth approximately $25,000. Accredited Wealth Management LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $36,000. Kentucky Trust Co acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $39,000. OFI Invest Asset Management purchased a new stake in Zimmer Biomet in the 4th quarter valued at $40,000. Finally, SRS Capital Advisors Inc. boosted its stake in Zimmer Biomet by 146.9% during the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 285 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity

In related news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Up 0.1 %

ZBH stock opened at $95.22 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.92 and a 12 month high of $122.25. The firm has a market capitalization of $18.84 billion, a PE ratio of 21.40, a P/E/G ratio of 1.95 and a beta of 0.78. The company’s 50 day simple moving average is $104.43 and its 200-day simple moving average is $106.12.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.94 earnings per share. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.01%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.24%.

Analyst Ratings Changes

ZBH has been the subject of several recent research reports. Royal Bank of Canada decreased their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Robert W. Baird cut their price target on Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Wells Fargo & Company lowered their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Finally, BTIG Research reissued a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $114.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.